Taysha Gene Therapies TSHA
NASDAQ TSHA
$4.74 -0.13 (-2.67%)
At close: Oct 1, 2026 · 4:00 PM EDT

Taysha Gene Therapies (TSHA) Liabilities and Shareholders Equity (2019 - 2026)

Updated

Taysha Gene Therapies' Liabilities and Shareholders Equity came in at $470.43 million for Q2 2026, up 41.1% from $333.33 million a year earlier and up 56.6% from the prior quarter.

Analysis

Taysha Gene Therapies (TSHA) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

At the end of FY2025, Taysha Gene Therapies' Liabilities and Shareholders Equity was $343.32 million, up 114.1% from FY2024.

  • Liabilities and Shareholders Equity carries a five-year compound annual growth rate of 5.8% (FY2020 to FY2025).
  • Going back by year, Liabilities and Shareholders Equity was $160.36 million in FY2024 (-7.2%), $172.73 million in FY2023 (+36.8%), $126.28 million in FY2022 (-41.0%) and $213.96 million in FY2021 (-17.4%).
  • The Q2 2026 figure represents the highest quarterly Liabilities and Shareholders Equity in data going back to Q4 2019.
  • Year-over-year, Liabilities and Shareholders Equity has increased for five consecutive quarters, with growth averaging 48.7% over the last eight quarters.
  • The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in Q2 2024 (growth of 145.8%), and the weakest in Q3 2022 (a decline of 53.8%).
  • Business Quant data shows TSHA's Liabilities and Shareholders Equity at $300.35 million (Q1 2026), $343.32 million (Q4 2025) and $316.55 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Taysha Gene Therapies 1.58 Bn 1.58 Bn - 470.43 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 470.43 Mn
Mar 31, 2026 300.35 Mn
Dec 31, 2025 343.32 Mn
Sep 30, 2025 316.55 Mn
Jun 30, 2025 333.33 Mn
Mar 31, 2025 138.36 Mn
Dec 31, 2024 160.36 Mn
Sep 30, 2024 180.22 Mn
Jun 30, 2024 200.39 Mn
Mar 31, 2024 153.00 Mn
Dec 31, 2023 172.73 Mn
Sep 30, 2023 195.77 Mn
Jun 30, 2023 81.54 Mn
Mar 31, 2023 101.60 Mn
Dec 31, 2022 126.28 Mn
Sep 30, 2022 111.47 Mn
Jun 30, 2022 142.33 Mn
Mar 31, 2022 165.98 Mn
Dec 31, 2021 213.96 Mn
Sep 30, 2021 241.04 Mn
API Access

Taysha Gene Therapies Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=TSHA&period=max&api_key=YOUR_API_KEY